Comparing the incidence of urinary incontinence in patients treated with and without endocrine therapy, a negative and statistically significant association was observed for the prescription of aromatase inhibitors; however, this finding may be influenced by residual confounding and indication bias. The gene discussed is CYP19A1; the disease is Urinary incontinence.